# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001493152-24-044224
Filing Date
2024-11-08
Accepted
2024-11-08 13:31:46
Documents
17
Period of Report
2024-11-08
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form8-k.htm iXBRL | 8-K | 40523
2 |  | ex99-1.htm | EX-99.1 | 28335
3 |  | ex99-2.htm | EX-99.2 | 923
4 |  | ex99-1_001.jpg | GRAPHIC | 13889
5 |  | ex99-2_001.jpg | GRAPHIC | 502351
| Complete submission text file | 0001493152-24-044224.txt |  | 966003

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL SCHEMA FILE | anix-20241108.xsd | EX-101.SCH | 3006
7 | XBRL LABEL FILE | anix-20241108_lab.xml | EX-101.LAB | 34240
8 | XBRL PRESENTATION FILE | anix-20241108_pre.xml | EX-101.PRE | 24159
19 | EXTRACTED XBRL INSTANCE DOCUMENT | form8-k_htm.xml | XML | 3741

Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 241439299
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)